Erythropoietin Stimulating Agents Market 2024-2028
The erythropoietin stimulating agents market is forecasted to grow by USD 4505.4 mn during 2023-2028, accelerating at a CAGR of 8.5% during the forecast period. The report on the erythropoietin stimulating agents market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by presence of large pool of ckd patients, rising applications in hiv infections and end-stage renal disorder, and risks of thrombosis, during surgeries, and pure red cell aplasia.
Technavio's erythropoietin stimulating agents market is segmented as below:
- By Type
- Epoetin alfa
- Epoetin beta
- Darbepoetin alfa
- Others
- By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the growing number of ckd dialysis centers in developing economies as one of the prime reasons driving the erythropoietin stimulating agents market growth during the next few years. Also, increasing instances of strategic collaborations among vendors and increasing investments in research and development for developing new and improved erythropoietin products will lead to sizable demand in the market.
The report on the erythropoietin stimulating agents market covers the following areas:
- Erythropoietin Stimulating Agents Market sizing
- Erythropoietin Stimulating Agents Market forecast
- Erythropoietin Stimulating Agents Market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading erythropoietin stimulating agents market vendors that include 3SBio Inc., Akebia Therapeutics, Amgen Inc., Biocon Ltd., Biosidus SA, Dr Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Johnson and Johnson Services Inc., Nanogen Pharmaceutical Biotechnology, NephroPlus, Novartis AG, Pfizer Inc., Reliance Industries Ltd., Renal Project, Thermo Fisher Scientific Inc., and Zydus Lifesciences Ltd.. Also, the erythropoietin stimulating agents market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.